{"preliminary_commentary":{"by_channel":{"x_thread":227,"youtube":62,"podcast":41,"bluesky_thread":9,"x_video":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03907488\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-10-29T04:52:12.767Z","note":"Automated from the 40 newest of 343 indexed sources (Jan 2026 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":40,"text":"- How to choose between N-AVD and BrECADD for individual patients\n- How end-of-treatment PET positivity should guide radiotherapy decisions\n- Whether real-world outcomes and tolerability support N-AVD use in older adults\n\nAlso discussed: EBV status and histology, ctDNA response assessment."},"drugs_tested":[["nivolumab"],["brentuximab vedotin"]],"indication":"newly diagnosed advanced-stage classical Hodgkin lymphoma","name":"S1826","nct_id":"NCT03907488","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=s1826-nct03907488. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, dacarbazine IV, and nivolumab IV over 30 minutes on days 1 and 15. Patients may receive pegfilgrastim SC on days 2 and 16, or filgrastim SC or IV on days 6-10 and 21-25. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 6, patients may receive radiation therapy 5 days per week for approximately 4 weeks at the discretion of the treating physician. Patients also undergo peripheral blood specimen collection and CT, PET/CT and MRI on study.","label":"Arm I (chemotherapy, nivolumab, radiation)","type":"EXPERIMENTAL"},{"description":"Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, dacarbazine IV, and brentuximab vedotin IV over 30 minutes on days 1 and 15. Patients may receive pegfilgrastim SC on days 2 and 16, or filgrastim SC or IV on days 6-10 and 21-25. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 6, patients may receive radiation therapy 5 days per week for approximately 4 weeks at the discretion of the treating physician. Patients also undergo peripheral blood specimen collection and CT, PET/CT and MRI on study.","label":"Arm II (chemotherapy, brentuximab vedotin, radiation)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-03-28","type":"ESTIMATED"},"conditions":["Ann Arbor Stage III Hodgkin Lymphoma","Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma","Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma","Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma","Ann Arbor Stage IV Hodgkin Lymphoma","Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma","Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma","Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma","Classic Hodgkin Lymphoma","Lymphocyte-Rich Classic Hodgkin Lymphoma"],"enrollment":{"count":994,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Biospecimen Collection","otherNames":["Biological Sample Collection","Biospecimen Collected","Sample Collection","Specimen Collection"],"type":"PROCEDURE"},{"name":"Brentuximab Vedotin","otherNames":["ADC SGN-35","Adcetris","Anti-CD30 Antibody-Drug Conjugate SGN-35","Anti-CD30 Monoclonal Antibody-MMAE SGN-35","Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35","cAC10-vcMMAE","SGN 35","SGN-35","SGN35"],"type":"DRUG"},{"name":"Computed Tomography","otherNames":["CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","Computerized Tomography (CT) scan","CT","CT Scan","Diagnostic CAT Scan","Diagnostic CAT Scan Service Type","tomography"],"type":"PROCEDURE"},{"name":"Dacarbazine","otherNames":["4-(Dimethyltriazeno)imidazole-5-carboxamide","5-(Dimethyltriazeno)imidazole-4-carboxamide","Asercit","Biocarbazine","Dacarbazina","Dacarbazina Almirall","Dacarbazine - DTIC","Dacatic","Dakarbazin","Deticene","Detimedac","DIC","Dimethyl (triazeno) imidazolecarboxamide","Dimethyl Triazeno Imidazol Carboxamide","Dimethyl Triazeno Imidazole Carboxamide","dimethyl-triazeno-imidazole carboxamide","Dimethyl-triazeno-imidazole-carboximide","DTIC","DTIC-Dome","Fauldetic","Imidazole Carboxamide","Imidazole Carboxamide Dimethyltriazeno","WR-139007"],"type":"DRUG"},{"name":"Doxorubicin Hydrochloride","otherNames":["5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)","ADM","Adriacin","Adriamycin","Adriamycin Hydrochloride","Adriamycin PFS","Adriamycin RDF","ADRIAMYCIN, HYDROCHLORIDE","Adriamycine","Adriblastina","Adriblastine","Adrimedac","Chloridrato de Doxorrubicina","DOX","DOXO-CELL","Doxolem","Doxorubicin HCl","Doxorubicin.HCl","Doxorubin","Farmiblastina","FI 106","FI-106","FI106","hydroxydaunorubicin","Rubex"],"type":"DRUG"},{"name":"Filgrastim","otherNames":["Filgrastim Biosimilar Filgrastim-sndz","Filgrastim Biosimilar Tbo-filgrastim","Filgrastim XM02","Filgrastim-aafi","Filgrastim-ayow","Filgrastim-sndz","G-CSF","Granix","Neupogen","Neutroval","Nivestim","Nivestym","r-metHuG-CSF","Recombinant Methionyl Human Granulocyte Colony Stimulating Factor","Releuko","rG-CSF","Tbo-filgrastim","Tevagrastim","XM02","Zarxio"],"type":"BIOLOGICAL"},{"name":"Magnetic Resonance Imaging","otherNames":["Magnetic Resonance","Magnetic Resonance Imaging (MRI)","Magnetic resonance imaging (procedure)","Magnetic Resonance Imaging Scan","Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance","MR","MR Imaging","MRI","MRI Scan","MRIs","NMR Imaging","NMRI","Nuclear Magnetic Resonance Imaging","sMRI","Structural MRI"],"type":"PROCEDURE"},{"name":"Nivolumab","otherNames":["ABP 206","BCD-263","BMS 936558","BMS-936558","BMS936558","CMAB819","MDX 1106","MDX-1106","MDX1106","NIVO","Nivolumab Biosimilar ABP 206","Nivolumab Biosimilar BCD-263","Nivolumab Biosimilar CMAB819","ONO 4538","ONO-4538","ONO4538","Opdivo"],"type":"BIOLOGICAL"},{"name":"Pegfilgrastim","otherNames":["Cegfila","Dulastin","Dyrupeg","Filgrastim SD-01","filgrastim-SD/01","Fulphila","Fylnetra","G-Lasta","Grasustek","HSP-130","Jinyouli","Neulasta","Neulastim","Neupopeg","Nyvepria","PEG-filgrastim","Pegcyte","Pegfilgrastim Biosimilar HSP-130","Pegfilgrastim Biosimilar Nyvepria","Pegfilgrastim Biosimilar Pegcyte","Pegfilgrastim Biosimilar PF-06881894","Pegfilgrastim Biosimilar Udenyca","Pegfilgrastim Biosimilar Ziextenzo","Pegfilgrastim-apgf","Pegfilgrastim-bmez","Pegfilgrastim-cbqv","Pegfilgrastim-cegf","Pegfilgrastim-dyru","Pegfilgrastim-fpgk","Pegfilgrastim-gras","Pegfilgrastim-jmdb","Pegfilgrastim-pbbk","Pegfilgrastim-pelg","Pegfilgrastim-pelm","Pegylated G-CSF","Pegylated GCSF","Pegylated Granulocyte Colony Stimulating Factor","Pelgraz","Pelmeg","PF-06881894","SD-01","SD-01 sustained duration G-CSF","Stimufend","Tripegfilgrastim","Udenyca","Ziextenzo"],"type":"BIOLOGICAL"},{"name":"Positron Emission Tomography","otherNames":["Medical Imaging, Positron Emission Tomography","PET","PET Scan","Positron emission tomography (procedure)","Positron Emission Tomography Scan","Positron-Emission Tomography","PT"],"type":"PROCEDURE"},{"name":"Quality-of-Life Assessment","otherNames":["Quality of Life Assessment"],"type":"OTHER"},{"name":"Questionnaire Administration","otherNames":[],"type":"OTHER"},{"name":"Radiation Therapy","otherNames":["Cancer Radiotherapy","Energy Type","ENERGY_TYPE","Irradiate","Irradiated","Irradiation","Radiation","Radiation Therapy, NOS","Radiotherapeutics","Radiotherapy","RT","Therapy, Radiation"],"type":"RADIATION"},{"name":"Vinblastine Sulfate","otherNames":["29060 LE","29060-LE","Exal","Velban","Velbe","Velsar","VINCALEUKOBLASTINE"],"type":"DRUG"}],"last_update":"2026-10-22","lead_sponsor":"National Cancer Institute (NCI)","official_title":"A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age &gt;/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-03-31","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS)","timeFrame":"From date of registration to date of first observation of progressive disease, or death due to any cause, assessed at 2 years"}],"references":[{"citation":"Goyal G, Lurain K, Lopez G, Rutherford SC, Castellino S, Davison K, Evens A, Smith SM, Kelly K, LeBlanc M, Song JY, Odeny T, Ratner L, Friedberg JW, Herrera AF. Nivolumab + Doxorubicin, Vinblastine, and Dacarbazine in HIV-Associated Advanced-Stage Classic Hodgkin Lymphoma. JCO Oncol Adv. 2026 Jan;3(1):e2500143. doi: 10.1200/oa-25-00143. Epub 2026 Feb 26.","pmid":"42577949","type":"DERIVED"},{"citation":"Ahmed S, Li H, Herrera AF, Perry AM, Kovach AE, Rutherford SC, Davison K, Castellino SM, Evens AM, Kahl BS, Bartlett N, Leonard JP, Shipp MA, Smith SM, Kelly KM, LeBlanc ML, Friedberg JW, Song JYY. Impact of EBV Status and Histology on Patient Outcomes with Nivolumab-AVD vs BV-AVD in Advanced Classic Hodgkin Lymphoma (S1826). Blood Adv. 2026 Jul 29:bloodadvances.2026021402. doi: 10.1182/bloodadvances.2026021402. Online ahead of print.","pmid":"42526889","type":"DERIVED"},{"citation":"Castellino SM, Li H, Herrera AF, LeBlanc M, Parsons SK, Unger JM, Punnett A, Hodgson D, Keller FG, Drachtman RA, Lamble A, Forlenza CJ, Doan A, Rutherford SC, Evens AM, Little RF, Smith MA, Hoppe BS, Song JY, Smith SM, Friedberg JW, Kelly KM. Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826. J Clin Oncol. 2026 Feb 20;44(6):449-454. doi: 10.1200/JCO-25-00203. Epub 2026 Jan 9.","pmid":"41512237","type":"DERIVED"},{"citation":"Herrera AF, LeBlanc M, Castellino SM, Li H, Rutherford SC, Evens AM, Davison K, Punnett A, Parsons SK, Ahmed S, Casulo C, Bartlett NL, Tuscano JM, Mei MG, Hess BT, Jacobs R, Saeed H, Torka P, Hu B, Moskowitz C, Kaur S, Goyal G, Forlenza C, Doan A, Lamble A, Kumar P, Chowdhury S, Brinker B, Sharma N, Singh A, Blum KA, Perry AM, Kovach AE, Hodgson D, Constine LS, Shields LK, Prica A, Dillon H, Little RF, Shipp MA, Crump M, Kahl B, Leonard JP, Smith SM, Song JY, Kelly KM, Friedberg JW. Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. N Engl J Med. 2024 Oct 17;391(15):1379-1389. doi: 10.1056/NEJMoa2405888.","pmid":"39413375","type":"DERIVED"},{"citation":"McKenna M, Ryu Tiger YK, Rutherford SC, Evens AM. The Management of older patients with Hodgkin lymphoma: implications of S1826. Semin Hematol. 2024 Aug;61(4):236-244. doi: 10.1053/j.seminhematol.2024.05.004. Epub 2024 Jun 4.","pmid":"38945791","type":"DERIVED"},{"citation":"Castellino SM, Giulino-Roth L, Harker-Murray P, Kahn JM, Forlenza C, Cho S, Hoppe B, Parsons SK, Kelly KM; COG Hodgkin Lymphoma Committee. Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30580. doi: 10.1002/pbc.30580. Epub 2023 Jul 28.","pmid":"37505794","type":"DERIVED"}],"start_date":{"date":"2019-08-29","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma","url":"https://clinicaltrials.gov/study/NCT03907488"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/s1826-nct03907488"}